210 related articles for article (PubMed ID: 27786097)
21. Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update.
Gozes I; Furman S
Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):623-40. PubMed ID: 15533779
[TBL] [Abstract][Full Text] [Related]
22. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
Delgado M; Jonakait GM; Ganea D
Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
[TBL] [Abstract][Full Text] [Related]
23. Advantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson's Disease.
Korkmaz OT; Tunçel N
Curr Pharm Des; 2018; 24(39):4693-4701. PubMed ID: 30636594
[TBL] [Abstract][Full Text] [Related]
24. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases.
Delgado M; Abad C; Martinez C; Juarranz MG; Arranz A; Gomariz RP; Leceta J
J Mol Med (Berl); 2002 Jan; 80(1):16-24. PubMed ID: 11862320
[TBL] [Abstract][Full Text] [Related]
25. Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions.
Chorny A; Gonzalez-Rey E; Varela N; Robledo G; Delgado M
Regul Pept; 2006 Nov; 137(1-2):67-74. PubMed ID: 16949684
[TBL] [Abstract][Full Text] [Related]
26. Microglia cells treated with synthetic vasoactive intestinal peptide or transduced with LentiVIP protect neuronal cells against degeneration.
Goksu AY; Kocanci FG; Akinci E; Demir-Dora D; Erendor F; Sanlioglu S; Uysal H
Eur J Neurosci; 2024 Apr; 59(8):1993-2015. PubMed ID: 38382910
[TBL] [Abstract][Full Text] [Related]
27. Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity.
Yadav M; Goetzl EJ
Ann N Y Acad Sci; 2008 Nov; 1144():83-9. PubMed ID: 19076367
[TBL] [Abstract][Full Text] [Related]
28. [The neuroprotective effect of PACAP, VIP, and derivatives in brain ischemia].
Jóźwiak-Bebenista M; Bednarek K; Nowak JZ
Postepy Hig Med Dosw (Online); 2008 Sep; 62():478-89. PubMed ID: 18806737
[TBL] [Abstract][Full Text] [Related]
29. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
Rangon CM; Goursaud S; Medja F; Lelièvre V; Mounien L; Husson I; Brabet P; Jégou S; Janet T; Gressens P
J Pharmacol Exp Ther; 2005 Aug; 314(2):745-52. PubMed ID: 15872042
[TBL] [Abstract][Full Text] [Related]
30. Vasoactive intestinal peptide in neurodevelopmental disorders: therapeutic potential.
Hill JM
Curr Pharm Des; 2007; 13(11):1079-89. PubMed ID: 17430171
[TBL] [Abstract][Full Text] [Related]
31. Induction by vasoactive intestinal peptide of interferon alpha/beta synthesis in glial cells but not in neurons.
Chelbi-Alix MK; Brouard A; Boissard C; Pelaprat D; Rostene W; Thang MN
J Cell Physiol; 1994 Jan; 158(1):47-54. PubMed ID: 7505279
[TBL] [Abstract][Full Text] [Related]
32. Vasoactive intestinal peptide protects against ischemic brain damage induced by focal cerebral ischemia in rats.
Yang J; Song TB; Zhao ZH; Qiu SD; Hu XD; Chang L
Brain Res; 2011 Jun; 1398():94-101. PubMed ID: 21620378
[TBL] [Abstract][Full Text] [Related]
33. Cardioprotective role of the VIP signaling system.
Dvoráková MC
Drug News Perspect; 2005; 18(6):387-91. PubMed ID: 16247516
[TBL] [Abstract][Full Text] [Related]
34. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors.
Groneberg DA; Rabe KF; Fischer A
Eur J Pharmacol; 2006 Mar; 533(1-3):182-94. PubMed ID: 16473346
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of VIP-induced neuroprotection against neonatal excitotoxicity.
Rangon CM; Dicou E; Goursaud S; Mounien L; Jégou S; Janet T; Muller JM; Lelièvre V; Gressens P
Ann N Y Acad Sci; 2006 Jul; 1070():512-7. PubMed ID: 16888217
[TBL] [Abstract][Full Text] [Related]
36. Clinical potential of VIP by modified pharmaco-kinetics and delivery mechanisms.
Burian B; Ortner A; Prassl R; Zimmer A; Mosgoeller W
Endocr Metab Immune Disord Drug Targets; 2012 Dec; 12(4):344-50. PubMed ID: 23094831
[TBL] [Abstract][Full Text] [Related]
37. The immunomodulator vasoactive intestinal peptide (VIP) does not affect experimental autoimmune uveitis (EAU) in B10.RIII mice.
Chen J; Vistica B; Wiggert B; Chan CC; Gery I
Ocul Immunol Inflamm; 2005 Feb; 13(1):13-7. PubMed ID: 15804764
[TBL] [Abstract][Full Text] [Related]
38. Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate.
Gozes I; Spivak-Pohis I
Curr Alzheimer Res; 2006 Jul; 3(3):197-9. PubMed ID: 16842095
[TBL] [Abstract][Full Text] [Related]
39. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide.
Keino H; Kezuka T; Takeuchi M; Yamakawa N; Hattori T; Usui M
Arch Ophthalmol; 2004 Aug; 122(8):1179-84. PubMed ID: 15302659
[TBL] [Abstract][Full Text] [Related]
40. Vasoactive intestinal peptide inhibits toll-like receptor 3-induced nitric oxide production in Schwann cells and subsequent sensory neuronal cell death in vitro.
Lee H; Park K; Kim JS; Lee SJ
J Neurosci Res; 2009 Jan; 87(1):171-8. PubMed ID: 18683246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
